RESUMO
Transmissible retroviruses encoding human hypoxanthine phosphoribosyltransferase (HPRT) were used to infect mouse bone marrow cells in vitro, and the infected cells were transplanted into mice. Both active human HPRT-protein and chronic HPRT-virus production were detected in hematopoietic tissue of the mice, showing transfer of the gene. These results indicate the possible use of retroviruses for somatic cell therapy.
Assuntos
Hipoxantina Fosforribosiltransferase/genética , Retroviridae/genética , Animais , Medula Óssea/microbiologia , Transplante de Medula Óssea , DNA Recombinante/metabolismo , Células-Tronco Hematopoéticas/microbiologia , Humanos , Isoenzimas/metabolismo , Síndrome de Lesch-Nyhan/genética , Síndrome de Lesch-Nyhan/terapia , Camundongos , Hibridização de Ácido Nucleico , Ratos , Retroviridae/enzimologia , Baço/microbiologiaRESUMO
The transfer of the human gene for hypoxanthine phosphoribosyltransferase (HPRT) into human bone marrow cells was accomplished by use of a retroviral vector. The cells were infected in vitro with a replication-incompetent murine retroviral vector that carried and expressed a mutant HPRT complementary DNA. The infected cells were superinfected with a helper virus and maintained in long-term culture. The production of progeny HPRT virus by the bone marrow cells was demonstrated with a colony formation assay on cultured HPRT-deficient, ouabain-resistant murine fibroblasts. Hematopoietic progenitor cells able to form colonies of granulocytes or macrophages (or both) in semisolid medium in the presence of colony stimulating factor were present in the nonadherent cell population. Colony forming units cloned in agar and subsequently cultured in liquid medium produced progeny HPRT virus, indicating infection of this class of hematopoietic progenitor cell.
Assuntos
Engenharia Genética , Células-Tronco Hematopoéticas/fisiologia , Hipoxantina Fosforribosiltransferase/genética , Retroviridae/genética , Animais , Células Cultivadas , Regulação da Expressão Gênica , Vetores Genéticos , Humanos , Camundongos , TransfecçãoRESUMO
Retroviral gene transfer to liver without prior injury has not yet been accomplished. We hypothesized that recombinant human keratinocyte growth factor would stimulate proliferation of hepatocytes and allow for efficient in vivo gene transfer with high titer murine Moloney retroviral vectors. This report shows that 48 h after intravenous injection of keratinocyte growth factor, hepatocyte proliferation increased approximately 40-fold compared to non-stimulated livers. When keratinocyte growth factor treatment was followed by intravenous injection of high titer (1 x 10(8) colony forming units/ml) retrovirus coding for the Escherichia Coli beta-galactosidase gene, there was a 600-fold increase in beta-galactosidase expression, with 2% of hepatocytes transduced. Thus, by exploiting the mitogenic properties of keratinocyte growth factor, retrovirus-mediated gene transfer to liver may be accomplished in vivo without the use of partial hepatectomy or pretreatment with other toxins to induce hepatocyte cell division.
Assuntos
Divisão Celular/efeitos dos fármacos , Fatores de Crescimento de Fibroblastos , Técnicas de Transferência de Genes , Substâncias de Crescimento/farmacologia , Animais , Células Cultivadas , Primers do DNA/química , Primers do DNA/genética , Escherichia coli/enzimologia , Escherichia coli/genética , Fator 10 de Crescimento de Fibroblastos , Fator 7 de Crescimento de Fibroblastos , Expressão Gênica/genética , Vetores Genéticos/genética , Vetores Genéticos/metabolismo , Imuno-Histoquímica , Óperon Lac/genética , Fígado/metabolismo , Camundongos , Reação em Cadeia da Polimerase , Retroviridae/metabolismo , Transdução Genética/genética , beta-Galactosidase/genética , beta-Galactosidase/metabolismoRESUMO
Several problems limit the application of gene transfer to correct the cystic fibrosis (CF) Cl(-) transport defect in airway epithelia. These include inefficient transduction with vectors applied to the apical surface, a low rate of division by airway epithelial cells, failure of transgene expression to persist, and immune responses to vectors or vector-encoded proteins. To address these issues, we used a feline immunodeficiency virus-based (FIV-based) vector. FIV vector formulated with a calcium chelator transduced fully differentiated, nondividing human airway epithelia when applied to the apical surface. FIV-based vector encoding the cystic fibrosis transmembrane conductance regulator cDNA corrected the Cl(-) transport defect in differentiated CF airway epithelia for the life of the culture (>3 months). When this approach was applied in vivo, FIV vector expressing beta-galactosidase transduced 1-14% of adult rabbit airway epithelia. Transduced cells were present in the conducting airways, bronchioles, and alveoli. Importantly, gene expression persisted, and cells with progenitor capacity were targeted. FIV-based lentiviral vectors may be useful for the treatment of genetic lung diseases such as CF. This article may have been published online in advance of the print edition.
Assuntos
Regulador de Condutância Transmembrana em Fibrose Cística/genética , Terapia Genética/métodos , Vírus da Imunodeficiência Felina/genética , Pulmão/patologia , Animais , Cloretos/metabolismo , Fibrose Cística/terapia , DNA Complementar/genética , Células Epiteliais , Técnicas de Transferência de Genes , Vetores Genéticos , Humanos , Fatores de Tempo , Traqueia/metabolismo , Transdução Genética , beta-Galactosidase/genéticaRESUMO
Human lymphoblasts deficient in the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT) were infected with an amphotropic helper-free retroviral vector expressing human HPRT cDNA. The stability and expression of the HPRT provirus in five cell lines with different proviral integration sites were examined by determining HPRT mutation and reversion frequencies and by blot hybridization studies. Mutation to the HPRT-negative phenotype occurred at frequencies of approximately 4 X 10(-5) to 3 X 10(-6) per generation. Most mutations in each of the five cell lines were associated with partial or complete deletions or rearrangements of the provirus. Several mutants retained a grossly intact HPRT provirus, and in one such mutant HPRT shutdown resulted from a revertible epigenetic mechanism that was not associated with global changes in proviral methylation. Therefore, mutation and shutdown of the HPRT provirus in human lymphoblasts result from mechanisms similar to those reported for several other avian and mammalian replication-competent retroviruses.
Assuntos
Genes Virais , Genes , Vetores Genéticos , Herpesvirus Humano 4/genética , Hipoxantina Fosforribosiltransferase/genética , Linhagem Celular , Transformação Celular Viral , DNA/análise , Humanos , Síndrome de Lesch-Nyhan/enzimologia , Mutação , Hibridização de Ácido NucleicoRESUMO
The dimeric aspartyl protease of HIV has been the subject of intense research for almost a decade. Knowledge of the substrate specificity and catalytic mechanism of this enzyme initially guided the development of several potent peptidomimetic small molecule inhibitors. More recently, the solution of the HIV protease structure led to the structure-based design of improved peptidomimetic and non-peptidomimetic antiviral compounds. Despite the qualified success of these inhibitors, the high mutation rate associated with RNA viruses continues to hamper the long-term clinical efficacy of HIV protease inhibitors. The dimeric nature of the viral protease has been conducive to the investigation of dominant-negative inhibitors of the enzyme. Some of these inhibitors are defective protease monomers that interact with functional monomers to form inactive protease heterodimers. An advantage of macromolecular inhibitors as compared to small-molecule inhibitors is the increased surface area of interaction between the inhibitor and the target gene product. Point mutations that preserve enzyme activity but confer resistance to small-molecule inhibitors are less likely to have an adverse effect on macromolecular interactions. The use of efficient retrovirus vectors has facilitated the delivery of these macromolecular inhibitors to primary human lymphocytes. The vector-transduced cells were less susceptible to HIV infection in vitro, and showed similar levels of protection compared to other macromolecular inhibitors of HIV replication, such as RevM10. These preliminary results encourage the further development of dominant-negative HIV protease inhibitors as a gene therapy-based antiviral strategy.
Assuntos
Inibidores da Protease de HIV/química , Protease de HIV/química , HIV-1/enzimologia , Retroviridae/genética , Sequência de Aminoácidos , Carbamatos , Furanos , Terapia Genética/métodos , Vetores Genéticos , Inibidores da Protease de HIV/síntese química , Humanos , Indinavir/química , Lentivirus/genética , Modelos Moleculares , Estrutura Molecular , Nelfinavir/química , Ritonavir/química , Saquinavir/química , Sulfonamidas/química , TransfecçãoRESUMO
OBJECTIVE: To demonstrate the safety and enhancement of HIV-1-specific immune responses in HIV-infected asymptomatic patients following treatment with retroviral vector (Retrovector)-transduced autologous fibroblasts (VTAF) expressing HIV-1IIIB Env/Rev proteins. DESIGN: A non-placebo-controlled, single arm Phase I study. PARTICIPANTS: Four HIV-1-seropositive asymptomatic volunteers were selected based on age (18-50 years), CD4/CD3 lymphocyte counts (> 600 x 10(6)/l or > 40%), and positive delayed-type hypersensitivity test to at least one recall antigen. INTERVENTIONS: Patients were treated at 2-week intervals with a total of three intramuscular injections of irradiated autologous fibroblasts transduced with a molecularly engineered, non-replicating amphotropic murine retrovector encoding the HIV-1IIIB Env/Rev proteins. MAIN OUTCOME MEASURES: The clinical status of patients was assessed by history, physical examination, serum chemistry and hematology, CD4/CD3 lymphocyte counts, HIV viral burden, and monitored throughout the study to detect potentially treatment-induced toxic or unwanted side-effects. In addition, HIV-1-specific cytotoxic T-lymphocyte (CTL) activity was measured to determine the biological activity of VTAF. RESULTS: No acute local or systemic adverse events occurred following three injections with VTAF. Furthermore, a statistically significant increase of CD8+ CTL activity against HIV-1IIIB Env/Rev-expressing targets was observed in peripheral blood mononuclear cells from two out of four patients. CONCLUSIONS: This is the first report of the administration of a gene transfer treatment to HIV-1-infected patients and provides initial support for the safety and activity of retrovector-transduced fibroblasts administered to asymptomatic patients. This treatment resulted in the detection of increased HIV-1IIIB Env/Rev-specific CTL activity in two HIV-seropositive patients and could provide a better understanding of the role of CTL activity in HIV disease progression.
Assuntos
Vacinas contra a AIDS/imunologia , Produtos do Gene env/imunologia , Produtos do Gene rev/imunologia , Soropositividade para HIV/imunologia , HIV-1/imunologia , Ativação Linfocitária , Linfócitos T Citotóxicos , Vacinas Sintéticas/imunologia , Adolescente , Adulto , Animais , Transplante de Células , Técnicas de Transferência de Genes , Vetores Genéticos , Soropositividade para HIV/terapia , Soropositividade para HIV/virologia , HIV-1/genética , Humanos , Camundongos , Pessoa de Meia-Idade , Transplante Autólogo/imunologia , Produtos do Gene rev do Vírus da Imunodeficiência HumanaRESUMO
Gene delivery via murine-based recombinant retroviral vectors is currently widely used in gene therapy clinical trials. The vectors are engineered to be replication defective by replacing the structural and nonstructural genes of a cloned infectious retrovirus with a therapeutic gene of interest. The retroviral particles are currently generated in packaging cell lines, which supply all retroviral proteins in trans. Recombination between short homologous regions of the retroviral vector and packaging cell line elements can theoretically generate replication-competent retrovirus (RCR) and hence the Food and Drug Administration (FDA) requires the monitoring of clinical trial subjects for the presence of RCR. Sensitive polymerase chain reaction (PCR) assays have been used for the detection of murine leukemia virus (MLV) nucleotide sequences in peripheral blood mononuclear cells (PBMCs). A novel serological enzyme-linked immunosorbent assay (ELISA) for the detection of anti-MLV specific immunoglobulin (Ig) has been developed to be used as an alternative to the PCR assay. Both assays were used to monitor human immunodeficiency virus (HIV)-positive clinical trial subjects who had received multiple injections of HIV-IT (V), a retroviral vector encoding HIV-1 IIIBenv/rev. Western blot analysis and an in vitro vector neutralization assay were used to characterize further a subset of serum samples tested by ELISA. Results show no evidence of RCR infection in clinical trial subjects. PCR and ELISA assays are discussed in terms of their advantages and limitations as routine screening assays for RCR. The PCR assay is our current choice for monitoring clinical trial subjects receiving direct administration of vector, and the ELISA is our choice for those receiving ex vivo treatment regimens.
Assuntos
Ensaio de Imunoadsorção Enzimática/métodos , Vetores Genéticos/uso terapêutico , Reação em Cadeia da Polimerase/métodos , Retroviridae/genética , Anticorpos Antivirais/análise , Anticorpos Antivirais/sangue , Ensaios Clínicos Fase I como Assunto , Estudos de Avaliação como Assunto , Vetores Genéticos/genética , Infecções por HIV/tratamento farmacológico , Infecções por HIV/genética , Infecções por HIV/virologia , Humanos , Vírus da Leucemia Murina/genética , Vírus da Leucemia Murina/imunologia , Replicação ViralRESUMO
Replication-incompetent retroviruses have been employed as gene therapy vectors in experimental settings for more than a decade. More recently, these vectors have been tested in the clinic as immunotherapeutic agents and anticancer agents. One potential problem with the use of such vectors is the possible development of immune responses directed against the vector particles themselves. Here, we examine immunoglobulin (Ig) responses specific for retroviral vectors derived from murine leukemia virus (MLV). Anti-MLV Ig is seen following intramuscular (i.m.) administration of retroviral vectors in mice, and in nonhuman primates; as expected, these responses are dependent upon the vector dose delivered. Furthermore, serum from vector-treated animals is capable of partially neutralizing vector-mediated transduction of target cells in an in vitro assay. Nevertheless, even in the presence of significant levels of anti-vector Ig in vivo, i.m. administration of retroviral vector is still capable of driving both Ig and cytotoxic T lymphocyte (CTL) responses specific for vector-encoded gene products. This work suggests that although retroviral vectors may readily induce immune responses directed against the vector particles themselves, such responses will not significantly affect the efficiency of these vectors in an immunotherapeutic protocol.
Assuntos
Vetores Genéticos/imunologia , Vetores Genéticos/farmacologia , Imunoglobulinas/efeitos dos fármacos , Imunoglobulinas/imunologia , Retroviridae/genética , Animais , Relação Dose-Resposta a Droga , Feminino , Vetores Genéticos/genética , Immunoblotting , Imunoglobulina G/efeitos dos fármacos , Imunoglobulina G/metabolismo , Vírus da Leucemia Murina/genética , Camundongos , Camundongos Endogâmicos BALB C , Testes de Neutralização , Primatas , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Retroviridae/imunologia , beta-Galactosidase/genética , beta-Galactosidase/imunologia , beta-Galactosidase/metabolismoRESUMO
Gene transfer with integrating vectors such as recombinant retrovirus has the potential to correct inherited lung diseases permanently. As a gene therapy target, the pulmonary epithelium presents several challenges to vector delivery in vivo. Many of the host defenses that have evolved to prevent infection from inhaled bacteria or viruses represent potential barriers to gene transfer to the lung. We performed in vitro studies to determine whether two components of the innate immune system of the lung, airway surface fluid and alveolar macrophages, inhibit retroviral gene transfer to airway epithelia. Human alveolar macrophages obtained by bronchoalveolar lavage from normal subjects were left untreated or activated with lipopolysaccharide (LPS) for 3 hr in the presence of subconfluent human bronchial epithelial cells (HBE); than 4 x 10(5) cfu DA-luciferase retrovirus was added. Three days after infection, luciferase activity was measured in cell lysates. When the epithelial cells were co-cultured with LPS-activated macrophages, retroviral gene transfer to HBE cells was reduced by approximately 60%. Nonactivated macrophages decreased the transfection to approximately 55% of control values. In control experiments with either activated or inactivated macrophages but without epithelia, no luciferase activity was detected, suggesting that terminally differentiated alveolar macrophages are not infected by the recombinant retrovirus. Pretreatment of alveolar macrophages with dexamethasone restored gene transfer to approximately 60% of control values. In contrast, incubation of retrovirus with airway surface fluid had no inhibitory effect on gene transfer. These experiments document that AM inhibit retrovirus-mediated gene transfer to airway epithelia in vitro, and may represent a barrier to retroviral gene transfer in vivo. These barriers may be overcome, at least partially, with pharmacological agents.
Assuntos
Técnicas de Transferência de Genes , Pulmão/fisiologia , Macrófagos Alveolares/fisiologia , Macrófagos Alveolares/virologia , Retroviridae/genética , Antineoplásicos Hormonais/farmacologia , Líquidos Corporais , Células Cultivadas , Dexametasona/farmacologia , Relação Dose-Resposta a Droga , Células Epiteliais , Epitélio/fisiologia , Epitélio/virologia , Vetores Genéticos/genética , Vetores Genéticos/farmacologia , Humanos , Pulmão/virologia , Macrófagos Alveolares/efeitos dos fármacosRESUMO
We have previously shown that intravenous administration of keratinocyte growth factor (KGF) induces hepatocyte proliferation, allowing for efficient and noninvasive in vivo gene transfer with high-titer retroviral vectors in mice. The distinctive periportal distribution of transduced cells led us to investigate the ability of virus-sized particles to perfuse the liver adequately after growth factor treatment. We found that perfusion was adequate, and that transduction was limited to the periportal region because only those cells were stimulated to divide. Cells in this region also showed increased expression of Ram-1, the receptor for the murine Moloney leukemia virus (MoMLV) amphotropic envelope, after KGF treatment. In further studies we found that recombinant hepatocyte growth factor (HGF) induces a different population of hepatocytes to divide and upregulate Ram-1. The differential pattern of induction suggested that combining KGF and HGF would improve gene transfer efficiency further. Indeed, simultaneous delivery of both growth factors leads to an overall increase in the number of proliferating cells. Importantly, when coupled with MoMLV delivery, efficiency of gene transfer increased. These results confirm the utility of growth factors for noninvasive hepatic gene transfer in mice, and demonstrate how experiments to define the mechanism of transduction can be taken advantage of to develop improved gene transfer protocols.
Assuntos
Fatores de Crescimento de Fibroblastos , Técnicas de Transferência de Genes , Substâncias de Crescimento/farmacologia , Fator de Crescimento de Hepatócito/farmacologia , Vírus da Leucemia Murina/genética , Fígado/efeitos dos fármacos , Animais , Divisão Celular/efeitos dos fármacos , Divisão Celular/genética , Fator 10 de Crescimento de Fibroblastos , Fator 7 de Crescimento de Fibroblastos , Vetores Genéticos , Hepatectomia , Imuno-Histoquímica , Fígado/citologia , Fígado/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Receptores Virais/genética , Transdução GenéticaRESUMO
In a phase 1 clinical trial, we are evaluating a murine leukemia virus (MuLV)-based retroviral vector encoding the human factor VIII gene [hFVIII(V)], administered intravenously, as a therapy for hemophilia A. Preclinical biolocalization studies in adult rabbits revealed vector-specific PCR signals in testis tissue at low levels. In follow-up animal studies we used PCR to (1) estimate the frequency with which a given cell in testis tissue is transduced, and (2) determine whether a positive PCR signal could be detected in semen samples from animals treated with hFVIII(V). Using the 99% confidence bound, results indicate that the probability that a given cell within the testis was transduced is less than 1/709,000 (97 days after treatment). This probability decreased with time after hFVIII(V) administration. Moreover, the rate of provector sequence detection in semen samples collected weekly throughout two cycles of spermatogenesis was 3/4281 reactions (0.07%), which is lower than the rate of false positives (1/800, 0.125%) observed for control animals. Using PCR assays with single-copy sensitivity, we have shown that the small number of transduced cells present in testis tissue does not give rise to detectable transduced cells in semen.
Assuntos
Fator VIII/genética , Retroviridae/genética , Sêmen/metabolismo , Testículo/metabolismo , Animais , Vetores Genéticos , Masculino , Modelos Biológicos , Modelos Estatísticos , Oligonucleotídeos/metabolismo , Reação em Cadeia da Polimerase , Coelhos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espermatogênese , Fatores de Tempo , Distribuição Tecidual , Transdução GenéticaRESUMO
Cytotoxic T lymphocyte (CTL) activity and CD4+ helper T cell responses to the hepatitis B virus (HBV) core antigen (HBcAg) have been implicated in clearance of acute and chronic HBV infections. We showed that intramuscular injections of a novel recombinant retroviral vector expressing an HBcAg-neomycin phosphotransferase II (HBc-NEO) fusion protein induces HBc/eAg-specific antibodies and CD4+ and CD8+ T cell responses in mice and rhesus monkeys. We have now immunized three chronically infected chimpanzees, each with 10(10) CFU of nonreplicating retroviral vector particles expressing the HBc-NEO fusion protein. Of two immunized chimpanzees examined for CTL responses, one developed HBcAg-specific CTLs and showed marginal, transient elevations of alanine aminotransferase (ALT) levels following injection. However, both chimpanzees remained positive for serum HBeAg, negative for anti-HBe antibody by conventional assays, and displayed no change in HBV viral load throughout the study. In contrast, the third chimpanzee exhibited a traditional seroconversion evidenced by a loss of serum HBeAg and the subsequent emergence of anti-HBe antibodies within 24 weeks after the first injection. Simultaneously, two transient ALT flares and a significant decrease in the serum HBV DNA levels were noted. Despite its limitations, the present study demonstrates (1) the safety of treatment with high titers of retroviral vector in chimpanzees, (2) the capability of a retroviral vector expressing HBcAg to stimulate immune responses in HBV chronic carrier chimpanzees, and (3) that retroviral vector immunization may be therapeutically beneficial in the treatment of chronic HBV infection.
Assuntos
Terapia Genética , Vetores Genéticos , Antígenos do Núcleo do Vírus da Hepatite B/genética , Hepatite B Crônica/terapia , Retroviridae/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Portador Sadio , Primers do DNA , DNA Viral/sangue , Modelos Animais de Doenças , Anticorpos Anti-Hepatite B/biossíntese , Vírus da Hepatite B/genética , Vírus da Hepatite B/isolamento & purificação , Hepatite B Crônica/imunologia , Humanos , Dados de Sequência Molecular , Pan troglodytes , Recombinação Genética , Homologia de Sequência de Aminoácidos , Linfócitos T Citotóxicos/imunologia , Carga ViralRESUMO
The translational stop codon TAA of the human hypoxanthine phosphoribosyltransferase (HPRT) cDNA has been changed to GAA by site-specific mutagenesis. This modification extends the open reading frame to a downstream stop codon and results in the addition of a unique negatively charged hexapeptide to the C terminus of human HPRT protein. The mutated cDNA was transferred into HPRT-deficient rodent cells by retroviral vector infection, and the expressed enzyme was found to be fully active. An antibody against a synthetic octapeptide corresponding to the mutated HPRT C terminus precipitated the HPRT protein specifically from cells infected with the mutant virus and not infected with the wild-type HPRT virus. The technique of inserting a novel epitope into a protein by site-directed mutagenesis should be generally applicable in studies of the regulation of gene expression in vitro and in vivo.
Assuntos
Hipoxantina Fosforribosiltransferase/genética , Epitopos/genética , Vetores Genéticos , Humanos , Concentração de Íons de Hidrogênio , Hipoxantina Fosforribosiltransferase/imunologia , Hipoxantina Fosforribosiltransferase/metabolismo , Técnicas Imunológicas , Mutação , Oligopeptídeos/imunologia , Terminação Traducional da Cadeia Peptídica , Relação Estrutura-Atividade , TransfecçãoRESUMO
A total of 17 patients with metastatic melanoma were treated with intratumoral interferon-gamma (IFN-gamma) retroviral vector in a phase I clinical trial. A cycle of treatment consisted of five daily injections every 2 weeks. Patients were divided into two treatment arms that involved a single course (one cycle) of treatment (group I; n = 9) and multiple cycles (six cycles) of treatment (group II; n = 8). Patients received intratumoral injections of IFN-gamma (10(7) plaque-forming units/mL administered at 0.3, 0.5, and 1.0 mL per cohort of patients). All patients receiving multiple injections either maintained stable disease (n = 5) or achieved a partial or complete response (n = 3) of the injected lesion, whereas in patients receiving a single cycle of treatment, only one of nine patients had a response. Patients were assessed for immunoglobulin G antibody (Ab) responses to the melanoma-associated antigens (MAA) tyrosinase, gp100, TRP-2, and MAGE-A1 by affinity enzyme-linked immunosorbent assay. Anti-MAGE-A1 and tyrosinase Ab were significantly elevated from baseline (day 0) to week 16 during treatment (P = .005; P = .002, respectively) in patients who received multiple injections. Patients undergoing treatment who had a clinical response (stable disease or better) also had significantly more elevated Ab responses to a greater number of MAA (P = .0004). The induction of systemic Ab responses to multiple MAA also correlated with systemic clinical responses. These studies suggest that multiple anti-MAA Ab responses are associated with clinical responses to IFN-gamma retroviral treatment and may be used as surrogate response markers.
Assuntos
Antígenos de Neoplasias/imunologia , Terapia Genética , Interferon gama/uso terapêutico , Melanoma/tratamento farmacológico , Glicoproteínas de Membrana/imunologia , Proteínas de Neoplasias/imunologia , Retroviridae/genética , Neoplasias Cutâneas/tratamento farmacológico , Adolescente , Antígenos de Neoplasias/genética , Estudos de Coortes , Primers do DNA/química , DNA de Neoplasias/análise , Ensaio de Imunoadsorção Enzimática , Vetores Genéticos , Humanos , Imunidade , Imunoglobulina G/imunologia , Injeções/métodos , Interferon Tipo I/genética , Interferon Tipo I/imunologia , Interferon gama/genética , Oxirredutases Intramoleculares/genética , Oxirredutases Intramoleculares/imunologia , Melanoma/genética , Melanoma/imunologia , Melanoma/patologia , Antígenos Específicos de Melanoma , Glicoproteínas de Membrana/genética , Monofenol Mono-Oxigenase/imunologia , Monofenol Mono-Oxigenase/metabolismo , Proteínas de Neoplasias/genética , Reação em Cadeia da Polimerase , Proteínas da Gravidez/genética , Proteínas da Gravidez/imunologia , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/patologia , Resultado do Tratamento , Antígeno gp100 de MelanomaRESUMO
In this review, we describe technical advancements of retroviral vectors to address issues of safety, titer, and clinical scale manufacturing to produce high-quality retroviral vector preparations that have made direct intratumoral administration of cytokine encoding recombinant vectors a feasible cancer therapy in the clinic. We also review possible further advances in retroviral vector design, which may prove important in expanding these clinical applications.
Assuntos
Citocinas/genética , Vetores Genéticos , Neoplasias/terapia , Retroviridae/genética , Vetores Genéticos/efeitos adversos , Vetores Genéticos/normas , HumanosRESUMO
Recombinant retroviral vectors can efficiently transduce and express foreign genes in mammalian cells. We have examined the utility of retroviral vector-mediated gene transfer to deliver genes which encode human immunodeficiency virus type I (HIV) antigens capable of stimulating specific immune responses. Murine fibroblast cell lines were transduced with a nonreplicating murine retroviral vector carrying the gene encoding the HIV-IIIB envelope protein and were shown to express the gp160/120 protein. Mice immunized with syngeneic vector-transduced cells developed CD8+, class I major histocompatibility complex (MHC)-restricted cytotoxic T lymphocytes (CTL) specific for targets expressing the HIV envelope protein. The CTL also exhibited lytic activity on target cells coated with synthetic peptides derived from the gp120 V3 hypervariable region of both the HIV-IIIB and HIV(MN) isolates. Following adoptive transfer in a murine tumor model, these CTL were shown to be effective in vivo by their ability to eliminate established tumor cells expressing the HIV protein. Vector-transduced syngeneic cells were also capable of eliciting HIV envelope-specific antibody responses in immunized mice. Sera obtained from these mice were found to bind to the HIV-IIIB gp160 protein as well as a peptide-defined neutralizing antibody epitope contained within the V3 domain of gp120. These sera exhibited virus-neutralizing activity in that they markedly reduced the ability of HIV to infect and form syncytia of a human T-cell line. This is the first demonstration that cells transduced with a retroviral vector encoding the HIV-IIIB envelope protein are capable of inducing effective HIV-specific cellular and humoral immune responses in mice.
Assuntos
Produtos do Gene env/imunologia , Vetores Genéticos , Anticorpos Anti-HIV/biossíntese , HIV-1/imunologia , Linfócitos T Citotóxicos/imunologia , Transdução Genética , Sequência de Aminoácidos , Animais , Linhagem Celular , Produtos do Gene env/genética , Humanos , Camundongos , Camundongos Endogâmicos , Camundongos Nus , Dados de Sequência Molecular , Retroviridae/genética , Especificidade da Espécie , TransfecçãoRESUMO
A retroviral vector-mediated gene transfer system was used to introduce m gamma-IFN and h gamma-IFN genes into mouse and human tumor cells, respectively. Murine tumor cell lines and primary human melanoma tumor cells were successfully transduced with gamma-IFN vector, and these transduced cells secreted measurable levels of biologically active m gamma-IFN and h gamma-IFN, respectively. Both murine and human tumor cell lines that expressed gamma-IFN exhibited increased surface expression of HLA class I antigens when tested by Western blot and FACS analysis. gamma-IFN--transduced human melanoma cells were more active in stimulating tumor-specific cytolytic activity of CTLs from melanoma patients in vitro. m gamma-IFN--transduced tumor cells were substantially less tumorigenic than the corresponding parent tumor cell lines in immune-competent mice. In addition, injection of m gamma-IFN--transduced tumor cells resulted in activation of tumor-specific CTL in vivo. We plan to use gamma-IFN--transduced autologous tumor cells to boost host immune responses as a potential therapy for human melanoma.
Assuntos
Técnicas de Transferência de Genes , Terapia Genética , Interferon gama/administração & dosagem , Animais , Linhagem Celular , Citotoxicidade Imunológica , Expressão Gênica , Vetores Genéticos , Antígenos HLA/imunologia , Humanos , Imunidade Celular , Complexo Principal de Histocompatibilidade , Melanoma/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Proteínas Recombinantes , Retroviridae/genética , Linfócitos T Citotóxicos/imunologia , Células Tumorais CultivadasRESUMO
A new method of producing vesicular stomatitis virus (VSV) G protein pseudotyped retroviral vectors is described. In this method, stocks of VSV-G pseudotyped vector were reproducibly obtained by infecting an env-, human, retroviral vector producer cell line with a recombinant murine cytomegalovirus (CMV) which expresses VSV-G protein. The recombinant murine CMV, RMCMVG, expressed VSV-G protein under transcriptional control of the human CMV immediate-early promoter. RMCMVG, like murine CMV, can infect human cells, but the infection is limited to the expression of the viral immediate-early genes; no productive replication of murine CMV occurs. Recombinant murine CMV vector infection of non-permissive cells may be useful in situations where high levels of gene expression are desired without concomitant viral vector replication.
Assuntos
Técnicas de Transferência de Genes , Vetores Genéticos/genética , Glicoproteínas de Membrana , Muromegalovirus/genética , Retroviridae/genética , Proteínas do Envelope Viral/biossíntese , Proteínas do Envelope Viral/genética , Células 3T3 , Animais , Linhagem Celular , Genes Virais/genética , Terapia Genética/métodos , Células Gigantes , Glicoproteínas/biossíntese , Glicoproteínas/genética , Humanos , Camundongos , Muromegalovirus/crescimento & desenvolvimento , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/genética , Recombinação Genética , Retroviridae/crescimento & desenvolvimento , Transfecção , Vírus da Estomatite Vesicular Indiana/genética , Ensaio de Placa ViralRESUMO
In the present study, we compared the therapeutic effect of tumor-selective retroviral replicating vectors (RRV) expressing the yeast cytosine deaminase (CD) delivered by convection-enhanced delivery (CED) or simple injection, followed by systemic administration of the pro-drug, 5-fluorocytosine (5-FC). Treatment with RRV-CD and systemic 5-FC significantly increased survival in rodent U87MG glioma model in comparison with controls (P<0.01). Interestingly, CED of RRV-CD followed by 5-FC further enhanced survival in this animal model in comparison with intra-tumoral injection of RRV-CD, followed by systemic 5-FC (P<0.05). High expression levels of Ki-67 were found in untreated tumors compared with treated. Untreated tumors were also much larger than treated. CED resulted in excellent distribution of RRV while only partial distribution of RRV was obtained after injection. Furthermore, RRV-CD and CD were also found in tumors from treated rats at study end points. These results demonstrated that RRV vectors may efficiently transduce and stably propagate in malignant human glioma, thereby achieving a significant in situ amplification effect after initial administration. We conclude that delivery of RRV into the glioma by CED provides much wider vector distribution than simple injection, and this correlated with better therapeutic outcomes.